KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EBIT (2016 - 2025)

NovoCure (NVCR) has disclosed EBIT for 12 consecutive years, with -$40.4 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 36.19% to -$40.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$153.8 million through Dec 2025, up 9.79% year-over-year, with the annual reading at -$153.8 million for FY2025, 9.79% up from the prior year.
  • EBIT hit -$40.4 million in Q4 2025 for NovoCure, down from -$36.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$88000.0 in Q1 2021 to a low of -$63.3 million in Q4 2024.
  • Historically, EBIT has averaged -$34.6 million across 5 years, with a median of -$36.9 million in 2025.
  • Biggest five-year swings in EBIT: surged 97.4% in 2021 and later plummeted 7375.06% in 2023.
  • Year by year, EBIT stood at -$23.4 million in 2021, then plummeted by 83.68% to -$43.0 million in 2022, then decreased by 20.33% to -$51.7 million in 2023, then decreased by 22.41% to -$63.3 million in 2024, then surged by 36.19% to -$40.4 million in 2025.
  • Business Quant data shows EBIT for NVCR at -$40.4 million in Q4 2025, -$36.0 million in Q3 2025, and -$39.5 million in Q2 2025.